Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma

Yajing Gao^{1,7#}, Pekka Päivinen^{1,2#}, Sushil Tripathi^{1,2#}, Eva Domenech-Moreno^{1,2}, Iris P.L. Wong¹, Kari
Vaahromeri³, Ashwini S. Nagaraj⁴, Sarang S. Talwelkar⁴, Marc Foretz⁵, Emmy W. Verschuren⁴, Benoit
Viollet⁵, Yan Yan^{1,6*}, Tomi P. Mäkelä^{1,2}

¹ iCAN Digital Precision Cancer Medicine Flagship and

² HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland

³ Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki
and Wihuri Research Institute, Finland

⁴ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,
Finland

⁵ Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France

⁶ Current address: Cancer Biology & Genetics Program, Sloan Kettering Institute, Memorial
Sloan Kettering Cancer Center, New York, USA

⁷ Current address: Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer
Center, New York, USA

#These authors contributed equally to this work.

Corresponding author: Yan Yan, Zuckerman Research Center, 417 East 68th Street, Room
ZRC-1331, New York, New York 10065. Email: yany@mskcc.org

Running title: Inactivation of AMPK leads to immune evasion in lung cancer.

Authors' disclosures:

Y. Gao is supported by Sigrid Juselius Foundation. Sushil Tripathi was supported by Academy of Finland postdoc fellowship and Instrumentarium Science Foundation. Y. Yan reports grants from Sigrid Juselius Foundation, Finnish Cultural Foundation, Maud Kuistila Memorial Foundation, Biomedicum Helsinki Foundation, Cancer Society of Finland, Paulo Foundation, University of Helsinki, Ida Montinin Foundation, K. Albin Johanssons Foundation, Instrumentarium Science Foundation and Otto A. Malm Foundation. EW Verschuren reports grants from European Union's Seventh Framework Programme and Academy of Finland. T.P. Mäkelä reports grants from Sigrid Juselius Foundation, Finnish Cancer Organizations, and Academy of Finland as well as personal fees from the European Commission outside the submitted work.

Conflicts of interest: The authors declare no potential conflicts of interest.

Word count: 5234; total number of figures and tables: 5.

41 **Statement of Translational relevance:** *LKB1* inactivation in NSCLC is clinically relevant as it
42 leads to resistance to immune checkpoint inhibitors. The findings of this study provide evidence
43 that this immune evasion is due to subsequent inactivation of AMPK and attenuation of antigen
44 presentation and suggest that restoration of AMPK activity could increase the number of patients
45 benefiting from immunotherapy. Furthermore, the study expands the correlation between
46 immune evasion and *LKB1* mutations to include a larger number of NSCLC without detectable
47 LKB1 mutation.

Abstract

Purpose: Mutations in *STK11 (LKB1)* occur in 17% of lung adenocarcinoma (LUAD) and drive a suppressive (cold) tumor immune microenvironment (TIME) and resistance to immunotherapy. The mechanisms underpinning the establishment and maintenance of a cold TIME in *LKB1* mutant LUAD remain poorly understood. In this study, we investigated the role of the LKB1 substrate AMPK in immune evasion in human NSCLC and mouse models and explored the mechanisms involved.

Experimental Design: We addressed the role of AMPK in immune evasion in NSCLC by correlating AMPK phosphorylation and immune suppressive signatures and by deleting *AMPK α 1 (Prkaa1)* and *AMPK α 2 (Prkaa2)* in a *Kras^{G12D}*-driven LUAD. Furthermore, we dissected the molecular mechanisms involved in immune evasion by comparing gene expression signatures, AMPK activity, and immune infiltration in mouse and human LUAD and gain or loss of function experiments with LKB1- or AMPK-deficient cell lines.

Results: Inactivation of both AMPK α 1 and AMPK α 2 together with Kras activation accelerated tumorigenesis and led to tumors with reduced infiltration of CD8⁺/CD4⁺ T cells and gene signatures associated with a suppressive TIME. These signatures recapitulate those in *Lkb1*-deleted murine LUAD and in *LKB1*-deficient human NSCLC. Interestingly a similar signature is noted in human NSCLC with low AMPK activity. In mechanistic studies we find that compromised LKB1 and AMPK activity leads to attenuated antigen presentation in both LUAD mouse models and human NSCLC.

Conclusions: The results provide evidence that the immune evasion noted in *LKB1* inactivated lung cancer is due to subsequent inactivation of AMPK and attenuation of antigen presentation.

Introduction

STK11/LKB1 mutations represent a challenge in non-small cell lung cancer (NSCLC) occurring in 17%-23% of NSCLC adenocarcinomas (1) often together with *KRAS*-activating mutations. Importantly, the presence of *LKB1* mutations or reduction of LKB1 expression in lung cancer patients associates with a more aggressive clinical phenotype (2) and resistance to conventional chemotherapy (3) as well as target therapies inhibiting either downstream effectors of *KRAS* signaling (4), suggesting novel therapeutic strategies are needed to target this subset of lung cancers. PD-1/PD-L1 checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers including NSCLC, yet not all patients respond. Retrospective studies in four independent cohorts identified genomic alterations of *STK11/LKB1* as a major driver of immune escape and tumor cell-intrinsic determinant of primary resistance to PD-1/PD-L1 blockade in NSCLC, despite the presence of intermediate or high tumor mutation burden (5). Consistently, a pan-tumor analysis of genomic markers associated with anti-PD-1 response demonstrated that tumor mutation burden (TMB) and a T cell-inflamed gene expression profile (GEP) can jointly stratify cancer patients into groups with different response to PD-1 blockade, with *LKB1* mutation in LUAD identified to have the most significant negative associations with T cell-inflamed GEP across 20 cancer types (6). These findings are recapitulated in a genetically engineered mouse model (GEMM) of lung cancer driven by oncogenic *Kras* mutation (*Kras*^{G12D}) where *Lkb1* inactivation leads to accelerated tumor growth (7), metastatic potential (7) and suppressed T-cell activity in the tumor immune microenvironment (TIME) (8).

STK11/LKB1 encodes a serine/threonine kinase activating at least 14 related kinases including AMPKs, NUAKEs, MARKs, SIKs and BRSKs and thereby regulates several cellular processes including cell metabolism, cell polarity, and growth (9). Using CRISPR/Cas9-mediated deletion

of these substrates, SIK1-3 deletion was noted to recapitulate the accelerated growth noted after *Lkb1* deletion in the *Kras*^{G12D} GEMM model (10, 11). The substrate(s) mediating effects on the tumor microenvironment and checkpoint inhibitor responses however remain to be identified.

The widely used antidiabetic drug metformin can reprogram the tumor microenvironment in lung cancer (12), esophageal squamous cell carcinoma (13) and colorectal cancer (14). As metformin also activates the LKB1 substrate AMPK (15), we hypothesized that inactivation of AMPK may contribute to the suppressive TIME in LKB1 deficient tumors. To address this, we investigated the association with AMPK activity and immune suppression in human lung cancer and generated GEMM models enabling inactivation of AMPK simultaneously with activation of *Kras* to investigate the causal role of AMPK in immune evasion.

Materials and Methods

Mice. All the experimental mouse strains (below) were generated from *Kras*^{LSL-G12D/+} (16), *Lkb1*^{fllox/fllox} (17), *AMPKα1*^{fl/fl} and *AMPKα2*^{fl/fl} (a kind gift from Benoit Violet) mice. The mice are in mixed genetic background of C57BL/6J and CD-1. All experiments utilized a mixture of female and male mice. Mice aged about 8-10 weeks were intranasally instilled with Ad5-CMV-Cre (5x10⁷ PFUs, University of Kupio, Finland) or Ad5-SPC-Cre (2.5x10⁹ PFUs) in 50μl MEM per mouse following the protocol previously described (18). Animals were housed in a pathogen-free facility at the Laboratory Animal Center of the University of Helsinki. Animal studies have been approved by the Finnish National Experiment Board (ESAVI/2327/04.10.07/2017).

Human lung cancer specimens. Surgically resected tumor specimens were received from NSCLC patients at the Hospital District of Helsinki and Uusimaa (HUS), as approved by the ethical board of the Joint Authority of the HUS, Finland (Dnro: 85/13/03/00/15). We obtained written informed consent from the patients and the studies were conducted in accordance with the Declaration of Helsinki.

Patient cohort. The Cancer Genome Atlas (TCGA) human lung adenocarcinoma (LUAD) bulk RNAseq datasets: PanCancer Atlas, TCGA (n = 566) (19), and Collisson et al. Nature, TCGA (n = 230) (1) with RSEM estimated batch normalized median expression values were downloaded from the cBioportal (<https://www.cbioportal.org/>). From these, *STK11/LKB1* mutant (*K*^{Mut}; *LKB1*^{Mut} = *KL*) and *KRAS* control (*K*^{Mut}; *LKB1*^{Wt} = *K*) samples were selected based on loss of function mutations in *LKB1*. Mutation data of the samples were accessed from the cBioportal (<https://www.cbioportal.org/>). The fold change difference in gene expression between *KL* and *K*

samples were calculated by computing Log2 ratio of the average expression values in *LKBI* mutant and *KRAS* control samples. To generate pAMPK transcriptomes, PanCancer Atlas LUAD cohort was accessed through cBioportal. Patients were queried for pAMPK (PROT: PRKAA1_PT172), as determined by reverse phase protein array (RPPA). Whole transcriptome, correlated with pAMPK, was uploaded using the *co-expression-tool*. To obtain pAMPK transcriptome specifically in *LKBI* wildtype patients, we excluded patients harboring genomic alterations in *LKBI* locus predicted to have oncogenic driver functions (query parameter DRIVER). For the Venn diagram, the overlap between *LKBI* mutations and pAMPK α patients were divided into high (Z-score ≥ 0) and low (Z-score < 0) pAMPK groups based on RPPA-values obtained through cBioportal. For the analysis of infiltration levels of different immune cells in PanCancer Atlas patients, precalculated xCell deconvolution results were uploaded from xCell web application (<https://xcell.ucsf.edu/>). Respective immune subpopulations were aggregated as following:

- CD8⁺ T-cells: CD8⁺ T-cells + CD8⁺ naïve T-cells + CD8⁺ Tcm + CD8⁺ Tem.
- CD4⁺ T-cells: CD4⁺ T-cells + CD4⁺ naïve T-cells + CD4⁺ Tcm + CD4⁺ Tem + CD4⁺ memory T-cells.
- Dendritic cells: DC + aDC + cDC + iDC + pDC
- Macrophages: Macrophages + Macrophages.M1 + Macrophages.M2
- B-cells: B-cells + Memory B-cells + Class-switched memory B-cells + naïve B-cells + Pro B-cells

Histology, immunohistochemistry. Human and murine lung samples were fixed (formalin for human samples; paraformaldehyde for murine samples), paraffin embedded, sectioned and immunohistochemistry stained as described earlier (20). The following primary antibodies were

used: TTF-1 (1:1000, ab133638, abcam), p63 (1:5000, ab124762, abcam), phospho-AMPK-
alpha (1:100, #2535, Cell Signaling), phospho-ACC (1:800, #3661, Cell Signaling), LKB1
(1:500, #13031, Cell Signaling), CD8 (1:200, #98941, Cell Signaling), CD4 (1:50, #25229, Cell
Signaling), CD3 (1:150, ab16669, abcam), B2M (1:1000, ab218230, abcam) and HLA Class I
ABC (1:150, ab70328, abcam). Stained slides were scanned with a digital slide scanner (3D
Histech Pannoramic 250 FLASH II).

RNA sequencing and data acquisition. About 10mg tumor tissue was dissected from RNAlater
(Thermo Fisher Scientific, AM7020) preserved lung tumor sample, and homogenized in Lysing
Matrix Tubes (MP, 6913-100) using Precellys 24 homogenizer (Bertin Instruments, P000669-
PR240-A) prior to RNA extraction with RNeasy Mini Kit (QIAGEN, 74104). mRNA-seq
libraries were prepared with the SureSelect Strand Specific RNA library prep kit (Agilent
Technologies) after PolyA capture, and then sequenced by single-end 75 base pairs using the
Illumina NextSeq 500 platform at Biomedicum Functional Genomics Unit. Sequenced reads
were aligned as described previously (20). Gene-wise aligned read counts were analyzed for
differential gene expression analysis using limma-voom R package
(<http://bioconductor.org/packages/release/bioc/html/limma.html>). For immune deconvolution of
mouse lung tumors, CIBERSORTx algorithm (<https://cibersortx.stanford.edu/>) was utilized using
default parameters using counts per million (cpm)-transformed expression matrix for mouse
tumor sequencing results. Custom gene sets for mouse CD8⁺ T-cell, CD4⁺ T-cells, dendritic
cells, monocytes, macrophages and B-cells were generated using published RNA-sequencing
data obtained from purified immune populations (GSE109125).

Immune Signature gene set

172 Human *KL* LUAD Immune Signature gene set was created by pooling unique genes from the
173 hallmark gene sets (1383 genes in total) listed in **Supplementary Table 1**. This provided a list of
174 973 unique genes (**Supplementary Table 2**) which were assigned as immune signature genes.
175 The list of immune signature genes were used as gene set to perform GSEA on fold change
176 ranked expressed genes in mouse *KL* and *KAA* datasets. The leading edge genes from the output
177 of this analysis in *KL* and *KAA* datasets were selected and log2 fold change values of the top 75
178 genes were visualized using pheatmap package in R (v3.6.2).

179 **Western blotting analysis.** Western blotting analysis was performed as described earlier (20).
180 The primary antibodies and their dilutions were as follows: LKB1 (1:2500, ab15095, abcam),
181 phospho-AMPKa (1:1000, #2535, CST), B2M (1:5000, ab75853, abcam), H3K27m3 (1:1000,
182 07-449, Merck Millipore), HLA Class I ABC (1:1000, ab70328, abcam) and GAPDH
183 (1:15000#2118, CST). Quantification of B2M protein level was performed using Image J: B2M
184 band sizes were normalized to that of GAPDH, and finally to corresponding empty vector
185 controls.

186 **Statistical analyses.** Statistical analyses were performed using GraphPad Prism 7.0c. Unpaired
187 2-tailed student T-test or Mann Whitney test was used to determine the significance between 2
188 groups, and Ordinary one-way ANOVA with Tukey's multiple comparisons test was used to
189 determine the significance among three groups. Log-rank (Mantel-Cox) test was used to
190 determine the significance of Kaplan-Meier plot. Data are presented as mean $\pm$ standard error
191 (s.e.m). Statistical significance was set at P-value of NS>0.05, *<0.05, **<0.01, ***<0.001, and
192 ****<0.0001.

193   **Data Availability Statement.** RNA sequencing data is available at Gene Expression Omnibus
194   under the accession number GSE175479.

195

196

Results

Correlation of *LKB1* mutations and attenuated AMPK activity with immune suppressive hallmarks in lung cancer patients

To interrogate how *LKB1* mutation impacts the tumor immune microenvironment (TIME), we made use of two large lung adenocarcinoma (LUAD) patient datasets (PanCancer Atlas, TCGA, 566 samples with RNASeq data from 510; Collisson et al. Nature, TCGA, 230 samples, named as Collisson dataset thereafter) (1) and compared the transcriptome between *STK11/LKB1* wildtype and mutant LUAD with *KRAS*-mutant background. We then probed for potentially relevant expression modules using Gene Expression Enrichment Analysis (GSEA) performed with the Molecular Signatures Database (MSigDB) hallmark gene set collection (**Fig. 1A and Supplementary Fig. 1A-C**). By using False Discovery Rate (FDR) < 0.05 as a cut-off, the analysis yielded 22 and 21 negatively enriched hallmark gene sets in PanCancer Atlas and Collisson datasets, respectively (**Fig. 1A and Supplementary Fig. 1A**). By ranking these hallmark gene sets according to their enrichment scores (NES values), 8 out of top 10 negative enriched hallmark gene sets are immune-related in both datasets (**Fig. 1A and Supplementary Fig. 1A**). These include ‘Interferon gamma response’, ‘TNF α signalling’ and ‘IL2-STAT5 signalling’ hallmarks representing genes with key roles in stimulating anti-tumor immune response and explored as targets for cancer immunotherapy (21). Taken together, these analyses demonstrated that *LKB1* mutant LUAD exhibit suppressive TIME, consistent with previous studies (5).

Given the availability of reverse phase protein array (RPPA)-derived data in subset of the PanCancer Atlas dataset (**Fig. 1C**), we sought to examine the possible association between TIME and phospho-AMPK α (pAMPK α ; Thr183 in AMPK α 1 and Thr172 in AMPK α 2)

phosphorylated by LKB1. Consistent with the notion that LKB1 is required for AMPK activation (9), we noted that LKB1 mutations were enriched in lo-pAMPK group (76%; green) as compared to hi-pAMPK group (23%; blue) (**Fig. 1C**). We then constructed a transcriptomic profile of LUAD with low pAMPK α (lo-pAMPK) by ranking (reversed) genes with respect to their correlation coefficients between gene expression and AMPK α phosphorylation level (low to high pAMPK α). Interestingly, the GSEA analysis indicated that lo-pAMPK was also associated with a suppressive TIME as evidenced by the same hallmarks identified (**Fig. 1B**), suggesting inactivation of AMPK could mediate the suppressive TIME in *LKB1* mutant LUAD. Importantly, digital deconvolution (xCell) of RNAseq data from PanCancer Atlas (TCGA) showed decreased infiltration of CD8⁺ and CD4⁺ T cells in lo-pAMPK LUAD (**Supplementary Fig. 2A-B**), further demonstrating that LUAD with attenuated AMPK activity is associated with suppressed TIME.

AMPK inactivation accelerates *Kras*-driven tumorigenesis and elicits suppressive tumor immune microenvironment

To establish whether the suppressive TIME observed in LUAD patient with lo-pAMPK is causally linked with AMPK inactivation, we crossed *Kras*^{LSL-G12D/+} mice with mice carrying *AMPK α 1*^{f/f} and *AMPK α 2*^{f/f} alleles or mice carrying *Lkb1*^{f/f} allele as a control leading to the generation of the following genotypes: (i) *Kras*^{LSL-G12D/+} (*K*); (ii) *Kras*^{LSL-G12D/+}; *Lkb1*^{f/f} (*KL*); (iii) *Kras*^{LSL-G12D/+}; *AMPK α 1*^{f/f}; *α 2*^{f/f} (*KAA*); (iiii) *AMPK α 1*^{f/f}; *α 2*^{f/f} (*AA*). Intranasal instillation of adenovirus expressing Cre-recombinase (Ad-Cre) in these mice activated *Kras*G12D in the lung epithelium and homozygous deletion of *Lkb1* in *KL* and *AMPK α 1* and *AMPK α 2* in *KAA* and *AA* mice (**Supplementary Fig. 3A**). Recombination of both *AMPK α 1* and *AMPK α 2* flox alleles from the dissected *KAA* tumors confirmed the deletion of *AMPK α 1* and *AMPK α 2*

(**Supplementary Fig. 3C**). Consistently, immunohistochemical staining (IHC) with phospho-Acetyl-CoA Carboxylase (pACC), phospho-AMPK α (p-AMPK α) and LKB1 antibodies on the serial sections from the lung tumors confirmed the reduced expression of Lkb1 in *KL* tumors and reduced pACC and pAMPK in both *KL* and *KAA* tumors (**Supplementary Fig. 3D**).

As expected (7), *KL* mice had a shortened median survival (45 days post Ad-Cre) as compared to *K* mice (170 days post Ad-Cre) (**Fig. 2A and Supplementary Fig. 3B**). Notably, *KAA* mice also had a significantly shortened survival (127 days post Ad-Cre) compared to *K* mice (**Supplementary Fig. 3B**), becoming progressively moribund with respiratory distress starting at 77 days (post Ad-Cre) as compared to 98 days of *K* mice (**Fig. 2A**). Consistently, at 90 days post Ad-Cre *KAA* lungs showed 1.8-fold increase in tumor burden compared to *K* mice (**Fig. 2B-C**). The acceleration of tumorigenesis in *KAA* mice are in line with a recent study using *in vivo* CRISPR/Cas9 mediated genome editing demonstrating that inactivation of AMPK α 1 and α 2 accelerate *Kras*-driven lung tumorigenesis albeit to lesser extent compared to inactivation of SIK family proteins (10). An earlier study (22) did not note accelerated tumorigenesis following AMPK which may be due to differences in background, approach or efficiency of recombination.

LKB1 loss has been shown to be associated with the appearance of tumors with squamous differentiation (7) in addition to adenocarcinomas. Based on staining with TTF-1 and p63 antibodies all tumors in the *KAA* mice represent adenocarcinomas (**Fig. 2D**), suggesting that other LKB1 substrates are involved in the squamous differentiation noted in *KL* tumors.

To investigate whether AMPK α 1/ α 2 inactivation has an impact on the TIME, we analysed T-cell infiltration in the tumors by staining and quantification (**Fig. 2E-F and Supplementary Fig. 3E**). In the control *KL* tumors a significant reduction of total T-cells (CD3⁺, 3.91% of total area in *K*

vs 1.49% in *KL*), cytotoxic T-cells (CD8⁺, 0.83% of total area in *K* vs 0.54% in *KL*) as well as helper T-cells (CD4⁺, 0.49% of total area in *K* vs 0.41% in *KL*) was noted as expected (5, 8, 23). Interestingly the *KAA* tumors also exhibited a reduction of infiltrated CD3⁺ (3.91% of total area in *K* vs 2.10% in *KAA*), CD8⁺ (0.83% of total area in *K* vs 0.50% in *KAA*) as well as CD4⁺ T-cells (0.49% of total area in *K* vs 0.35% in *KAA*) indicating AMPK loss fosters a non-T-cell-inflamed TIME in *Kras*-driven LUAD similarly to *Lkb1* loss.

Identification of an immune suppressive transcriptomic signature in AMPK-deficient *Kras*-driven lung adenocarcinoma

To characterize the tumor microenvironment of *KL* and *KAA* mouse tumors in greater detail, we measured global gene expression changes by RNA-seq from primary tumors micro-dissected from *K*, *KL* and *KAA* lungs. Unbiased GSEA analysis on the fold-change ranked expressed genes in *KAA* lung tumors showed strong negative enrichment of immune signature gene sets - 6 of top 10 hallmark gene sets were immune-related, including interferon and inflammatory responses similarly to *KL* tumors (**Fig. 3A**). Consistent with the TCGA LUAD study (1) as well a study of syngeneic tumor model with *Lkb1* deficiency (5), our results did not provide evidence for neutrophil enrichment as noted in one study (8). Next, we compared the *KAA* mouse model with *KL* human LUAD (*KLI*, PanCancer Atlas, TCGA; *KL2* (1)), lo-pAMPK human LUAD (Low pAMPK; *LKBI* wildtype) as well as the *KL* LUAD mouse model by comparing GSEA hallmarks of each (**Fig. 3B and Supplementary Fig. 4A**). Remarkably, the sets enriched in *KAA* shared a striking overall similarity with *KL* and lo-pAMPK patient sets with several immune-related hallmarks. Interestingly *KAA* GSEA analysis demonstrated a higher similarity to human sets than the *KL* mouse model, which as expected (5, 8) also displayed negative enrichment of several immune-related hallmarks (**Fig. 3B**). Furthermore, deconvolution analysis using CIBERSORTx

(<https://cibersortx.stanford.edu/>), a computational method for quantifying cell fractions from bulk RNAseq profiles, validated the decreased infiltration of CD8⁺ T cells in both *KL* and *KAA* as well as CD4⁺ T cells in *KAA* LUAD (**Supplementary Fig. 4B**). Therefore, these results are in line with our IHC analysis (**Fig. 2E-F and Supplementary Fig. 3E**) and provide evidence, at the molecular level, that AMPK inactivation drives a suppressive TIME with high similarity to human *LKB1* mutant LUAD suggesting a major role for AMPK in mediating LKB1 effects on immune evasion.

To further delineate clinically relevant mechanisms and genes that could contribute to the immune evasion observed in both *KL* and *KAA* mouse LUAD, we derived an Immune Signature gene set consisting of 973 genes (**Supplementary Table 1**) by pooling unique genes from 8 immune function related hallmark gene sets (**Supplementary Table 1**) in the *KL* human LUAD datasets (see Materials and Methods, **Fig. 3B**) and performed GSEA in both *KL* and *KAA* mouse LUAD. The analysis revealed significant enrichment of the human *KL* LUAD immune signature (Immune Signature) gene set in both *KL* and *KAA* mouse LUAD, and notably the significance was much more profound in *KAA* than *KL* mouse LUAD (**Fig. 3C**). To gain further mechanistic insight into downstream pathways potentially mediating the suppressive immune signature in both *KL* and *KAA* LUAD, we performed leading edge gene analysis from the GSEA (Immune Signature) of both *KL* and *KAA* mouse LUAD (ranked by GSEA of *KAA* LUAD, **Fig. 3D**) and focused on genes intrinsic to the tumor cells. We found both *KL* and *KAA* tumors have suppressed expression of antigen processing and presentation related genes, including *Nlrc5*, *B2m* (**Fig. 3D-E and Supplementary Fig. 4C**). Notably, both *NLRC5* and *B2M* are frequently downregulated in many different cancers by enabling immune evasion (24, 25), and a recent study identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2)

in epigenetically modulating the regulation of *NLR5* and antigen presentation pathway including *B2M* (26). Indeed, both murine (*KAA* and *KL*) and human (*KL* and lo-pAMPK) LUAD display significantly suppressed expression of PRC2 target genes (**Supplementary Fig. 4E**), corroborating with previous reports on the regulation of PRC2/EZH2 activity by either AMPK (27) or LKB1 (28). Notably, treatment of *LKB1* mutant NSCLC cells line A549 with EZH2 inhibitor GSK126 led to restoration of B2M and HLA Class Ia expression with concomitant downregulation of H3K27me3 (**Supplementary Fig. 4D**), suggesting that PRC2/EZH2 activation could be a potential mechanism to silence antigen presentation pathway and elicit the evasive TIME in *LKB1* mutant LUAD. Taken together, these analyses demonstrate that the immune signature of *KL* human LUAD is recapitulated by AMPK inactivation and therefore provide further evidence for the contribution of AMPK inactivation to the suppressive TIME in *KL* LUAD.

AMPK inactivation downregulates MHC Class I genes

Antitumor immune response depends on the recognition of tumor-specific neoantigens presented through human leukocyte antigen class I (HLA-I)-encoded major histocompatibility complex (MHC) class I molecules by cytotoxic T-cells (CD8⁺) (29). Recently, loss of heterozygosity (LOH) at the *HLA-I* loci (30)(31) and homozygous loss of β 2-microglobulin (*B2M*) or downregulation of B2M expression (25) have been identified as a mechanism of immune evasion and resistance to immune checkpoint inhibitors (ICI) in multiple cancer types including NSCLC. We noted that B2M was significantly reduced in both *KL* and *KAA* mouse LUAD at both transcriptional level (**Fig. 3E and Supplementary Fig. 4C**) and by immunohistochemistry (**Fig. 4A and 4B**). Importantly, *B2M* was also reduced in human *KL* LUAD cohorts (**Fig. 4C**) and accompanied by reduction of several MHC class I genes (*HLA-B*, *HLA-C*, *HLA-E* and *HLA-F*)

(**Supplementary Fig. 5A**) as well as immunoproteasome related genes (*PSMB8*, *PSMB9*, *PSMB10* and *UBE2L6*) (**Supplementary Fig. 5B**) as noted by a recent study in human *KL* LUAD (32). The reduction of *B2M* expression was also noted in human lung cancer cell lines (Cancer Cell Line Encyclopedia, **Supplementary Fig. 5C**) demonstrating the reduction in a tumor cell intrinsic mechanism. To investigate the relationship between AMPK activity and *B2M* levels more directly, we reconstituted *LKB1* null A549 human LUAD cells (*Kras*^{G12S};*LKB1*^{-/-}) with a constitutively active AMPK α 1 (AMPK α 1-T183E). Interestingly, reconstitution of AMPK α 1 activity by AMPK α 1-T183E increased *B2M* levels significantly and comparably to reconstitution of *LKB1*. As expected, expression of wild-type AMPK α 1 was not sufficient to reconstitute AMPK activity in cell line without *LKB1* (**Fig. 4D and Supplementary Fig. 5D**).

Reduced AMPK activity in LUAD associated with attenuated expression of antigen presentation components and immune evasion

To investigate whether low pAMPK α associated with expression of antigen presentation genes we compared the mRNA expression of *B2M* and MHC class I chain encoding genes between pAMPK high and low LUAD with wildtype *LKB1*. The results indicated that *B2M* (**Fig. 5A**) as well as all the MHC class I chain encoding genes (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-E*, *HLA-F* and *HLA-G*) were significantly downregulated in human LUAD with reduced pAMPK (lo-pAMPK, *LKB1* wildtype, **Supplementary Fig. 6A**). Similar to the observation in mouse *KAA* and *KL* LUAD, the MHC class I transactivator *NLRC5* was downregulated in lo-pAMPK (*LKB1* wildtype, **Fig. 5B**) and *KL* human LUAD (**Supplementary Fig. 6B**). Consistent with *KL* patients (**Supplementary Fig. 5B**), we also noted suppressed expression of immunoproteasome components in *LKB1* wildtype patients with lo-pAMPK (**Supplementary Fig. 6C**). Previous

analysis of large collection of NSCLC tissue microarray samples (more than 400) revealed that the surface expression of *B2M* and *HLA class I* genes correlates with infiltration of CD8⁺ cytotoxic T cell in the tumors (33). Thus, we compared the composition of T cells between pAMPK high (hi-pAMPK) and low (lo-pAMPK) LUAD by digital deconvolution (xCell) of RNAseq data from PanCancer Atlas (TCGA) in cases where *LKB1* mutations were not identified. Interestingly, lo-pAMPK was associated with decreased infiltration of CD8⁺ (**Fig. 5C**) and CD4⁺ (**Fig. 5D**) T cells, similar to LUAD with identified *LKB1* mutations as well as with *KL* and *KAA* mouse LUAD. Strikingly, the LUAD cases with low pAMPK (lo-pAMPK, **Fig. 5E**) extended significantly beyond cases with identified *LKB1* mutations suggesting that AMPK inactivation is sufficient to attenuate antigen presentation and immune evasion in human LUAD.

Discussion

Our study provides evidence that the clinically relevant immune evasion noted in *LKB1* mutant lung cancer is due to subsequent inactivation of AMPK and attenuation of antigen presentation.

The identification of AMPK as a mediator of immune evasion provides important mechanistic insight and potential target for therapeutic intervention. The observation complements the earlier reports that the LKB1 substrates MARK1 and MARK4 are required for LKB1 to suppress the EMT transcription factor Snail and metastasis (34) and that the LKB1 substrates SIK1 and SIK3 are required for growth suppression by LKB1 in lung cells (11, 35). Whether the immune evasion noted in this study following AMPK loss – and not studied by others – is causally associated with accelerated progression remains to be resolved thoroughly. Furthermore, our study (using Cre/LoxP mediated AMPK knockout) is consistent with Murray et al 2019 (using CRISPR/Cas9 mediated gene editing) (35) as we both observed increased tumor area/burden (**Fig. 2B and 2C in this study and Fig. 1D and 1F in Murray et al 2019**) albeit at variable degrees, whereas Eichner et al 2019 did not observe increased tumorigenesis using either Ad-Cre or Lenti-Cre induced Cre/LoxP mediated AMPK knockout (22). While one trivial explanation might be due to the lower AdCre dose used in Eichner et al 2019 (1×10^6 PFU vs 5×10^7 PFU in this study), it is notable that in both murine *KL* mice – which displays enhanced tumor growth compared to *K* mice (36) – and *LKB1* mutant NSCLC cell lines (37) as well as primary tumors (this study) both AMPK phosphorylation and AMPK dependent phosphorylation of ACC are nearly completely abrogated, suggesting that inactivation of AMPK is associated with tumor growth in *LKB1*-mutant NSCLC. Together these results suggest that LKB1 substrates mediate specific downstream effects of LKB1 contributing to tumor suppression and provides a rationale for not finding the substrates inactivated alone in human cancers.

Consistent with increasing evidence that cancer cells can evade immune surveillance by attenuating antigen presentation machinery (APM) (38), we identified reduction of several APM components including B2M, the scaffolding component of MHC-I complex, in both human and mouse *KL* LUAD, mouse *KAA* LUAD as well as in human LUAD with reduced pAMPK α (lo-pAMPK). This is consistent with the observed co-regulation of APM components (39) to meet with local requirements for an adequate immune response (39) by master regulators such as NLRC5 (39). Interestingly, *NLRC5* is downregulated in both *KL* and *KAA* mouse LUAD (**Fig. 3D-E**) as well as in human *KL* LUAD (**Supplementary Fig. 6B**) and lo-pAMPK LUAD (**Fig. 5B**), providing evidence for NLRC5 as a potential mediator for the regulation of APM genes by LKB1 via AMPK. A potential link between AMPK, NLRC5 and APM components is provided by the observations that AMPK suppresses the PRC2 histone methylase complex through phosphorylation of that PRC2 suppresses NLRC5 and APM components to enable immune evasion in multiple cancer types (26). This is consistent with our observation that also other PRC2 targets are downregulated in both human and mouse *KL* and *KAA* (lo-pAMPK) LUAD (**Supplementary Fig. 4E**) and that EZH2 inhibition led to upregulation of B2m and HLA Class Ia expression in *LKB1* mutant NSCLC cell line (**Supplementary Fig. 4D**). Taken together, these observations provide a possible mechanism for the decreased antigen presentation following defects in LKB1 whereby the resulting inactivation of AMPK enables PRC2 to suppress NLRC5 and APM components such as B2M.

The study identified attenuated phospho-AMPK α (lo-pAMPK) as a new biomarker associating with a suppressive TIME. This is interesting from a clinical point of view as: i) a suppressive TIME has been associated with resistance to PD-1 immunotherapy (6); ii) *LKB1* mutations represent the most prevalent identified mechanism of primary resistance to PD-1/PD-L1 axis

inhibitors in LUAD (5); and iii) the remarkable similarity of the TIME in *LKB1* mutant and lo-pAMPK LUAD (this study). As the landscape of primary resistance to PD-1 immunotherapy in LUAD is not fully understood and the current approaches to investigate loss of LKB1 by mutation screens (40) or LKB1 staining (2) may not be comprehensive due to e.g. non-genomic alterations (41) or defects in cofactors required for LKB1 function (42), there is a clear unmet need for new biomarkers to predict checkpoint therapy resistance.

The results here indicate lo-pAMPK represents not only a potential surrogate biomarker for LKB1 inactivation (**Fig. 5E**) but more importantly a biomarker identifying a larger LUAD set with attenuation of the pathway critical for maintenance of antigen presentation. In PanCancer Atlas patients for which both genomic and phosphorylation data was available, lo-pAMPK was noted not only in 39 patients with identified *LKB1* mutations, but importantly in 114 additional patients with a similar suppressed TIME (**Fig. 3B and Fig. 5C-D**) and reduced APM genes (**Fig. 5A-B and Supplementary Fig. 6A-B**) as those with *LKB1* mutations. This suggests that the primary resistance to PD-1 immunotherapy noted in *LKB1* mutant LUAD (5) could extend to the additional patients with lo-pAMPK but without an identified *LKB1* mutation. It will be interesting to investigate whether in the additional lo-pAMPK patients LKB1 inactivation had gone undetected (2) or whether there might be alternative ways to attenuate AMPK (43–45). However, from a clinical standpoint the discovery of lo-pAMPK identifying an enlarged set of patients with a suppressive TIME suggests that investigating the potential of lo-pAMPK in predicting primary resistance to PD-1/PD-L1 immunotherapy in LUAD patients is a priority. Based on the our initial attempt with limited amount of NSCLC patient samples, it is notable that pAMPK and B2M are both absent in *LKB1* mutant tumor (**Supplementary Fig. 6D**) prompting future efforts with extended patient samples to validate the utility of pAMPK IHC as a biomarker.

Acknowledgements

We thank Saara Ollila and Elina Niemelä for insightful discussions and Saana Ruusulampi and Melissa Montrose for technical assistance. We thank Gonghong Wei and Qin Zhang for constructive suggestions and help with LUAD patient data analysis. We thank Kaisa Salmenkivi from the Department of Radiology and Pathology at Uusimaa Hospital District (HUS) and Jere Linden from Finnish Center for Laboratory Animal Pathology for histology and pathology examination. We thank Laboratory Animal Center, Genome Biology Unit and Biomedicum Functional Genomics Unit for excellent service.

References

1. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network. *Nature* 2014; 511: 543-550.
2. Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, et al. Immunohistochemical Loss of LKB1 Is a biomarker for more aggressive biology in KRAS-mutant lung Adenocarcinoma. *En: Clinical Cancer Research*. American Association for Cancer Research Inc., pp. 2851-2860.
3. Bonanno L, Paoli A De, Zulato E, Esposito G, Calabrese F, Favaretto A, et al. LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. *Clin Cancer Res* 2017; 23: 3316-3324.
4. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature* 2012; 483: 613-617.
5. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. *Cancer Discov* 2018; 8: 822-835.
6. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* (80-); 362. Epub ahead of print 2018. DOI: 10.1126/science.aar3593.
7. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. *Nature* 2007; 448: 807-810.
8. Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. *Cancer Res* 2016; 76: 999-1008.
9. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* 2009; 9: 563-575.

- 477 10. Murray CW, Brady JJ, Tsai MK, Li C, Winters IP, Tang R, et al. An LKB1-SIK Axis Suppresses
478 Lung Tumor Growth and Controls Differentiation. *Cancer Discov* 2019; 9: 1590-605.
- 479 11. Hollstein PE, Eichner LJ, Brun SN, Kamireddy A, Svensson RU, Vera LI, et al. The AMPK-
480 Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
481 *Cancer Discov* 2019; 9: 1606-1633.
- 482 12. Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin Enhances the Antitumor Activity
483 of CD8 + T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway. *J Immunol* 2020; 204:
484 2575-2588.
- 485 13. Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-Dose Metformin Reprograms the
486 Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical
487 Trial. *Clin Cancer Res* 2020; 26: 4921-4932.
- 488 14. Saito A, Kitayama J, Horie H, Koinuma K, Ohzawa H, Yamaguchi H, et al. Metformin changes
489 the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus.
490 *Cancer Sci* 2020; 111: 4012-4020.
- 491 15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein
492 kinase in mechanism of metformin action. *J Clin Invest* 2001; 108: 1167-1174.
- 493 16. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung
494 tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev* 2001;
495 15: 3243-3248.
- 496 17. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, et al. Loss of the
497 Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. *Nature*
498 2002; 419: 162-167.
- 499 18. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or
500 lentiviral delivery of Cre recombinase. *Nat Protoc* 2009; 4: 1064-1072.
- 501 19. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An Integrated
502 TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

503 Cell 2018; 173: 400-416.e11.

504 20. Gao Y, Yan Y, Tripathi S, Penttimikko N, Amaral A, Päivinen P, et al. LKB1 Represses ATOH1
505 via PDK4 and Energy Metabolism and Regulates Intestinal Stem Cell Fate. *Gastroenterology* 2020;
506 158: 1389-1401.e10.

507 21. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al.
508 Cytokines in clinical cancer immunotherapy. *Br J Cancer* 2019; 120: 6-15.

509 22. Eichner LJ, Brun SN, Ross DS, Shaw RJ, Svensson RU. Genetic Analysis Reveals AMPK Is
510 Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. *Cell Metab*
511 2019; 29: 285-302.

512 23. Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. TP53, STK11,
513 and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung
514 adenocarcinoma. *Clin Cancer Res* 2018; 24: 5710-5723.

515 24. Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. NLRC5/CITA: A Key Player in Cancer Immune
516 Surveillance. *Trends in Cancer* 2017; 3: 28-38.

517 25. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class I antigen
518 processing and presentation as a mechanism of acquired resistance to immune checkpoint
519 inhibitors in lung cancer. *Cancer Discov* 2017; 7: 1420-1435.

520 26. Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An Evolutionarily
521 Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and
522 Enables Immune Evasion in Cancer. *Cancer Cell* 2019; 36: 385-401.e8.

523 27. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, et al. Phosphorylation of EZH2 by AMPK
524 Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. *Mol Cell* 2018; 69: 279-
525 291.e5.

526 28. Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, et al. Suppression of
527 STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. *Cancer Discov* 2019; 9: 34-45.

528 29. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC

529 Class I Antigen Presentation. *Front Immunol* 2021; 12: 636568.

530 30. Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, et al. Somatic HLA Class I
531 Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor
532 Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. *Cancer Discov* 2021; 11:
533 282-292.

534 31. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-
535 Specific HLA Loss and Immune Escape in Lung Cancer Evolution. *Cell* 2017; 171: 1259-
536 1271.e11.

537 32. Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes
538 compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer.
539 *Nat Cancer* 2021; 2: 503-514.

540 33. Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, et al. Genomic Profiling of
541 Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing
542 Immunorecognition. *Clin Cancer Res* 2017; 23: 3203-3213.

543 34. Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE, Shaw RJ. An AMPK-independent
544 signaling pathway downstream of the LKB1 tumor suppressor controls *snail1* and metastatic
545 potential. *Mol Cell* 2014; 55: 436-450.

546 35. Murray CW, Brady JJ, Tsai MK, Li C, Winters IP, Tang R, et al. An *lkb1*–*sik* axis suppresses lung
547 tumor growth and controls differentiation. *Cancer Discov* 2019; 9: 1590-1605.

548 36. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung
549 cancer differentiation and metastasis. *Nature* 2007; 448: 807-10.

550 37. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, et al. Dysfunctional AMPK
551 activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient
552 lung cancer. *Oncogene* 2007 2611 2006; 26: 1616-1625.

553 38. Shukla A, Cloutier M, Santharam MA, Ramanathan S, Ilangumaran S. The mhc class-i
554 transactivator *nlrc5*: Implications to cancer immunology and potential applications to cancer

555 immunotherapy. *Int J Mol Sci* 2021; 22: 1-36.

556 39. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC
557 Class I Antigen Presentation. *Front Immunol* 2021; 12: 636568.

558 40. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.
559 *Oncogene* 2007; 26: 7825-7832.

560 41. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of
561 LKB1/STK11 Is a Common Event in Adenocarcinomas of the Lung. *Cancer Res*; 62.

562 42. Kullmann L, Krahn MP. Controlling the master - Upstream regulation of the tumor suppressor
563 LKB1. *Oncogene* 2018; 37: 3045-3057.

564 43. Yan Y, Ollila S, Wong IPL, Vallenius T, Palvimo JJ, Vaahtomeri K, et al. SUMOylation of
565 AMPK α 1 by PIAS4 specifically regulates mTORC1 signalling. *Nat Commun* 2015; 6: 1-12.

566 44. Suzuki T, Bridges D, Nakada D, Skiniotis G, Morrison SJ, Lin JD, et al. Inhibition of AMPK
567 catabolic action by GSK3. *Mol Cell* 2013; 50: 407-419.

568 45. Budanov A V., Karin M. p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and
569 mTOR Signaling. *Cell* 2008; 134: 451-460.

570

571

Figure Legends

Fig. 1. Transcriptomic immune signatures suppressed in lung adenocarcinoma patients with either *LKB1* mutations or with attenuated phospho-AMPK α .

A. Negatively enriched Molecular Signatures Database (MSigDB) hallmark gene sets in *LKB1* mutant lung adenocarcinoma (LUAD) patients with identified *LKB1* inactivating mutations compared to controls (*KRAS* mutant in both sets) in PanCancer Atlas (TCGA) as analysed by gene set enrichment analysis (GSEA) and ranked by normalized enrichment scores (NES). Immune-related hallmarks are shown in red. NES in sets with a false discovery rate (FDR) < 0.05 are in red.

B. GSEA analysis as in A showing negatively enriched hallmarks in LUAD samples with low phospho-AMPK α (lo-pAMPK; including both *LKB1* wild-type and mutant samples, see Fig. 1C and Materials and Methods) as a biomarker for AMPK activity.

C. Oncoprint depicting the percentage of human lung adenocarcinomas (510 samples, PanCancer Atlas, TCGA) that have been profiled with RPPA (Reverse Phase Protein Arrays) into either hi-pAMPK (in blue) or lo-pAMPK (in green), and that harbour distinct genomic alterations of *LKB1* and *KRAS*.

Fig. 2. Deletion of AMPK α 1 and AMPK α 2 accelerates *Kras*-driven lung adenocarcinoma and elicits a suppressive tumor immune microenvironment.

A. Kaplan-Meier curve of *Kras*^{LSL-G12D/+} (termed K; n=27), *Kras*^{LSL-G12D/+};*Lkb1*^{fl/fl} (termed KL; n=27), *Kras*^{LSL-G12D/+};*AMPK α 1*^{fl/fl};*AMPK α 2*^{fl/fl} (termed KAA; n=25) and *AMPK α 1*^{fl/fl};*AMPK α 2*^{fl/fl} (termed AA; n=12) mice after inhalation with 5x10⁷ PFU of Ad-CRE. Log-rank (Mantel-Cox) test was used to determine significance: **** P<0.0001 for K vs KAA; **** P<0.0001 for K vs KL; **** P<0.0001 for KL vs KAA.

- B. Representative micrographs of hematoxylin and eosin (H&E) stained left lobes of *K* and *KAA* mice 90 days post-inhalation demonstrating increased tumors burden.
- C. Quantification of tumor burden (total tumor area/total lung area) in both *K* (n=7) and *KAA* (n=7) mice 90 days post-inhalation. Unpaired *t* test (two-tailed) was used to determine the significance (*P < 0.05; ** *P* < 0.01; *** *P* < 0.001).
- D. H&E, TTF-1 or p63 staining of lung serial sections from *K*, *KL* or *KAA* mice with tumors classified as adenocarcinoma (ADC) or squamous cell carcinoma (SCC).
- E. CD8 or CD4 immunohistochemical staining of *K*, *KL* and *KAA* lung tumor sections.
- F. Quantification of CD8⁺ and CD4⁺ cells in tumors from indicated mouse strains as determined by percentage of marker positive surface area in IHC stained lung tumors. Each dot represents a single tumor and multiple tumors were quantified from each genotype. The largest tumor containing lobe from each mouse was selected for quantification. Minimum 4 mice per genotype were used for quantification. Number of tumors quantified for CD8⁺ T cells: *K*, n=20; *KL*, n=14; *KAA*, n=75. Number of tumors quantified for CD4⁺ T cells quantification: *K*, n=28; *KL*, n=16; *KAA*, n=49. Unpaired *t* test (two-tailed) was used to determine the significance (*P < 0.05; ** *P* < 0.01; *** *P* < 0.001).

Fig. 3. Identifying immune suppressive transcriptomic signatures in LUAD with attenuated AMPK

- A. MSigDB Hallmark gene sets associated with AMPK α deficient *Kras*-driven LUAD (*KAA* vs *K*) as determined by GSEA and ranked by NES. The immune related hallmarks are shown in red. Hallmarks with false discovery rate (FDR) < 0.05 are shown.

B. Dot plot illustrating cross-species GSEA enrichment scores for MSigDB Hallmark gene sets from *KL* human LUAD (*KL1*, PanCancer Atlas, TCGA; *KL2*, Collisson et al. Nature 2014, TCGA), *LKB1* wildtype human LUAD with reduced pAMPK (lo-pAMPK) as well as *KL* and *KAA* mouse LUAD. NES is indicated by color and FDR is indicated by dot size. The plot is ranked by NES of *KL1* and immune-related hallmarks are highlighted in red.

C. GSEA enrichment plots representing negative enrichment of Human *KL* LUAD immune signature (Immune Signature; see material and methods) in *KAA* and *KL* tumors.

D. Leading edge gene analysis showing top 75 negatively enriched Immune Signature genes as a heatmap of fold changes in *KL* and *KAA* lung tumors ranked by GSEA of *KAA* LUAD and with antigen presentation/immunoproteasome related genes highlighted in red. The colour bars on top show the correlation between colour and log fold-change of the indicated genes.

E. Relative mRNA level of *B2m*, *Nlrp5*, *H2-K1*, *H2-D1* and *H2-T23* from mouse primary tumors micro dissected from *K*, *KL* or *KAA* lungs as assessed by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. 3 tumors from each genotype were used for analysis. Unpaired *t* test (two-tailed) was used to determine the significance (*P < 0.05; ** *P* < 0.01; *** *P* < 0.001).

Fig. 4. Attenuation of the MHC Class I component β 2-microglobulin following defects in LKB1 or AMPK in lung cancer.

A. Representative IHC staining of B2m in *K*, *KL* and *KAA* lung tumors. Scale bar: 100 μ m.

B. Quantification of B2M⁺ cells in tumors from indicated mouse strains as determined by percentage of marker positive surface area in IHC stained lung tumors. Each dot

represents each tumor and multiple tumors were quantified from each genotype. The largest tumor containing lobe from each mouse was selected for quantification. Minimum 4 mice per genotype were used for quantification. Number of tumors quantified for B2m⁺ cells: *K*, n=199; *KL*, n=84; *KAA*, n=173. Unpaired t test (two-tailed) was used to determine the significance (*P < 0.05; ** P < 0.01; *** P < 0.001).

C. Dot plot graph showing RNA-sequencing by expectation maximization (RSEM) of *B2M* mRNA expression values in *K* (*KRAS* mutant and *LKB1* wildtype) or *KL* (*KRAS* mutant and *LKB1* mutant) LUAD in PanCancer Atlas (TCGA) or Collisson et al. Nature 2014 (TCGA). Number of samples in PanCancer Atlas: *K*, n=128; *KL*, n=38. Number of samples in Collisson et al. Nature 2014: *K*, n=62; *KL*, n=20. Mann Whitney test was used to determine the significance (*P < 0.05; ** P < 0.01; *** P < 0.001).

D. Western blotting analysis of cell lysates from A549 cells stably transduced with a control lentiviral vector (Control) or lentiviral constructs expressing indicated cDNAs shown on the top using antibodies indicated on the left. LKB1-K78M: kinase-deficient LKB1; LKB1-WT: wild-type LKB1; AMPK α 1-WT: wild-type AMPK α 1; AMPK α 1-T183E: constitutively active AMPK α 1.

Fig. 5. Attenuated pAMPK as a new biomarker identifying an extended set of LUAD patients with defective antigen presentation and immune evasion.

A. Dot plot showing *B2M* mRNA expression values (by RSEM) in high (hi) or low (lo) pAMPK (*LKB1* wildtype) LUAD patients (top and bottom 15th percentiles respectively) from the PanCancer Atlas (TCGA). Number of samples: hi-pAMPK, n=46; lo-pAMPK, n=46. Mann Whitney test was used to determine the significance (*P < 0.05; ** P < 0.01; *** P < 0.001).

B. Comparison of NLRC5 in hi or lo-pAMPK LUAD analysed as in **A**. Number of samples: hi-pAMPK, n=46; lo-pAMPK, n=46.

C. Dot plot graph showing CD8⁺ T-cells deconvolution scores, as determined by digital deconvolution (xCell), in hi or lo-pAMPK LUAD (*LKB1* wildtype) patients (top and bottom 15th percentiles respectively) in PanCancer Atlas (TCGA). Number of samples: hi-pAMPK, n=46; lo-pAMPK, n=46.

D. Dot plot graph showing CD4⁺ T-cells infiltration levels, determined as in **D**. Number of samples: hi-pAMPK, n=46; lo-pAMPK, n=46. Mann Whitney test was used to determine the significance from **A-D** (*P < 0.05; ** P < 0.01; *** P < 0.001).

E. Left: Levels of pAMPK assayed by Reverse Phase Protein Arrays (RPPA) in patients binned to hi-pAMPK (n=188; *LKB1* wildtype) and lo-pAMPK (n=114; *LKB1* wildtype) compared to *LKB1* mutant LUAD patients (n=51). Ordinary one-way ANOVA with Tukey's multiple comparisons test was used to determine the significance among the three groups. (*P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.001). **Right:** Venn diagram illustrating the overlap of LUAD patients with hi-pAMPK (blue; 200 patients) and lo-pAMPK (green; 153 patients), where phospho-AMPK α was determined by RPPA, with LUAD patients with identified *LKB1* mutations (red, 51 patients).

Figure 1

A

LKB1 mutant LUAD
(Negatively enriched)

B

lo-pAMPK LUAD
(Negatively enriched)

C

Figure 2

Figure 3

A Hallmarks associated with AMPK deletion (KAA vs K in mouse LUAD)

B GSEA across human and mouse LUAD

Figure 4

A

B

C

D

Figure 5

Supplementary Materials and Methods

Image quantification. To quantitate lung tumor size, individual tumor areas and total lung areas were measured from H&E stained sections using ImageJ and the percentage of tumor area was normalized to total lung area. To quantitate immune cell infiltration level, tumors were annotated using CaseViewer software (3DHISTECH). Only tumors negative for phospho-ACC staining from *KL* and *KAA* mice were included in the analysis. For *KL*, squamous tumors were excluded from quantification. Annotations were analyzed using QuantCenter software (HistoQuant, 3DHISTECH) by recording the fraction of DAB-positive surface area. The largest tumor containing lobe from each mouse was selected for quantification and minimum 4 mice per genotype were quantified.

Plasmids. For lentiviral expression, lentiviral vector (pLenti6/V5) expressing human *LKB1* (wildtype), *LKB1*-K78M (kinase dead mutant), *AMPK α 1* (wildtype) and *AMPK α 1*-T183E (mutant) were generated.

Cell culture, lentiviral production and transduction. *KAA* mouse embryonic fibroblast cells (MEFs) were generated using a method described earlier (2). Adenoviral infection was performed as previously described (3). A549 and HEK293FT cell were purchased from ATCC in 1996 and regularly checked for mycoplasma contamination (monthly, LookOut@Mycoplasma PCR Detection Kit, MP0035, Sigma) during the course this study. Cells were not authenticated and all cell lines were used for experiments within 5 passages after thawing. For EZH2 inhibition experiment, A549 cells were treated with EZH2 inhibitor GSK126 (5 μ M, #15415, Cayman Chemicals) for 7 days before analysing by western blot. Recombinant lentivirus production and

transduction were described earlier (2). Transduced A549 cells were selected with 5 μ g/ml blasticidin (15205, Sigma-Aldrich).

Real-Time Quantitative Polymerase Chain Reaction. Total RNA of lung tumor samples were isolated as described earlier (1). Reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR) were described earlier (2), with primers listed below. Relative messenger RNA (mRNA) levels were calculated relative to mouse β -actin.

Mm_Bactin_Fwd:	CTAAGGCCAACCGTGAAAAG
Mm_Bactin_Rev:	ACCAGAGGCATACAGGGACA
Mm_B2m_Fwd:	CCCGCCTCACATTGAAATCC
Mm_B2m_Rev:	TCACATGTCTCGATCCCAGT
Mm_Nlrc5_Fwd:	CAGCTATGAGCCCTCCAACC
Mm_Nlrc5_Rev:	GTTTGGCACCATGGTACAGC
Mm_H2-D1_Fwd:	TGAGGAACCTGCTCGGCTACTA
Mm_H2-D1_Rev:	GGTCTTCGTTCAGGGCGATGTA
Mm_H2-K1_Fwd:	GGCAATGAGCAGAGTTTCCGAG
Mm_H2-K1_Rev:	CCACTTCACAGCCAGAGATCAC
Mm_H2-T23_Fwd:	CTCGCTGCGGTATTTACCA
Mm_H2-T23_Rev:	AGCGTGTGAGATTCGTCGT

Recombination measurements and PCR. Tumor and adjacent tissue samples were dissected from PFA fixed lungs, and purified DNA using QIAamp DNA FFPE Tissue Kit (QIAGEN, 56404). The PCR reactions were prepared with the following contents: 100ng genomic DNA, 5 μ M of each PCR primer listed as below, GoTaq DNA polymerase (Promega, M3005) and H₂O. PCR condition of KrasG12D: 95°C-5 min, 95°C-30 sec, 61°C-30 sec, 72°C-45 sec, 35 cycles, 72°C-10

min, 4°C-hold. PCR condition of AMPK flox and recombined alleles: 95°C-5 min, 95°C-30 sec, 58°C-30 sec, 72°C-10 sec, 35 cycles, 72°C-2 min. 4°C-hold.

<i>KrasG12D</i> _Primer 1:	GTCTTTCCCCAGCACAGTGC
<i>KrasG12D</i> _Primer 2:	CTCTTGCCTACGCCACCAGCTC
<i>KrasG12D</i> _Primer 3:	AGCTAGCCATGGCTTGAGTAAGTCTGCA
AMPK α 1_flox_Fwd:	AATAGCCCATGAGCTCCAGA
AMPK α 1_flox_Rev:	TGCAGCCCTACACTGAAATG
AMPK α 2_flox_Fwd:	ATGGCTTGGCGCTGTCTA
AMPK α 2_flox_Rev:	ACTTTCTGGCCAGGCAGATG
AMPK α 1_rec_Fwd:	CCCATGAGCTCCAGAAGAAG
AMPK α 1_rec_Rev:	GCCAGACACAGGTGAAGACA
AMPK α 2_rec_Fwd:	GATCTGTCTGCTTCTGCGTTC
AMPK α 2_rec_Rev:	CGATGGCCGCTCTAGATAAC

Gene set enrichment analysis

The gene set enrichment analysis (GSEA) (<https://www.gsea-msigdb.org/gsea/index.jsp>) was performed on fold-change ranked expressed genes in human *KL* TCGA LUAD datasets and mouse *KL* and *KAA* datasets. For the pAMPK α in TCGA LUAD dataset, Spearman correlation coefficient was used as a ranking criteria. For PRC2-related gene sets, ranked lists for human and mouse RNA-sequencing results were probed against BENPORATH_PRC2_TARGETS, BENPORATH_SUZ12_TARGETS and BENPORATH_EED_TARGETS. The results were visualized and interpreted using ggplot2 package in R (v3.6.2).

Cancer Cell Line Encyclopedia. We focused on the analysis of non-small cell lung cancer cell lines. Reads per kilobase per million (RPKM) values for *B2M* were obtained from Broad Institute

Cancer Cell Line Encyclopedia data portal (CCLE portal, <https://portals.broadinstitute.org/ccle>).

Mutation statuses for *KRAS* and *LKB1* were obtained from cBioportal.

Reference:

1. Gao Y, Yan Y, Tripathi S, Pentinmikko N, Amaral A, Päivinen P, et al. LKB1 Represses ATOH1 via PDK4 and Energy Metabolism and Regulates Intestinal Stem Cell Fate. *Gastroenterology* 2020; 158: 1389-1401.e10.
2. Yan Y, Ollila S, Wong IP, Vallenius T, Palvimo JJ, Vaahtomeri K, et al. SUMOylation of AMPK α 1 by PIAS4 specifically regulates mTORC1 signalling. *Nat Commun* 2015; 6: 8979.
3. Vaahtomeri K, Ventelä E, Laajanen K, Katajisto P, Wipff PJ, Hinz B, et al. Lkb1 is required for TGF β -mediated myofibroblast differentiation. *J Cell Sci* 2008; 121: 3531-3540.